PURPOSE: Chronic myeloid leukemia (CML) patients are monitored by both cytogenetic and molecular assessments, although present guidelines appear to switch from cytogenetic to molecular criteria. Due to the increasing use of molecular measurements, it was the aim of this work to identify a BCR-ABL level according to the international scale (BCR-ABL(IS)) as an equivalent substitute for complete cytogenetic remission (CCyR). METHODS: In total, 1,329 paired data from 557 patients of the German CML-Study IV were evaluated. The data set was divided into a learning set and a validation set. The best cutoff was determined applying a minimal p value approach to the Fisher test. RESULTS: In the learning set, we found BCR-ABL(IS) values between 0.2 and 1.1 % were well suited for predicting a CCyR. In the validation set, the cutoff level of 1 % led to a mean concordance rate of 90.1 %. CONCLUSIONS: Our results suggest that there is no one-to-one cutoff for BCR-ABL(IS) representing CCyR, but we advise to use the 1 % BCR-ABL(IS) in order to avoid misclassification of CCyR patients.
PURPOSE:Chronic myeloid leukemia (CML) patients are monitored by both cytogenetic and molecular assessments, although present guidelines appear to switch from cytogenetic to molecular criteria. Due to the increasing use of molecular measurements, it was the aim of this work to identify a BCR-ABL level according to the international scale (BCR-ABL(IS)) as an equivalent substitute for complete cytogenetic remission (CCyR). METHODS: In total, 1,329 paired data from 557 patients of the German CML-Study IV were evaluated. The data set was divided into a learning set and a validation set. The best cutoff was determined applying a minimal p value approach to the Fisher test. RESULTS: In the learning set, we found BCR-ABL(IS) values between 0.2 and 1.1 % were well suited for predicting a CCyR. In the validation set, the cutoff level of 1 % led to a mean concordance rate of 90.1 %. CONCLUSIONS: Our results suggest that there is no one-to-one cutoff for BCR-ABL(IS) representing CCyR, but we advise to use the 1 % BCR-ABL(IS) in order to avoid misclassification of CCyR patients.
Authors: Timothy P Hughes; Andreas Hochhaus; Susan Branford; Martin C Müller; Jaspal S Kaeda; Letizia Foroni; Brian J Druker; François Guilhot; Richard A Larson; Stephen G O'Brien; Marc S Rudoltz; Manisha Mone; Elisabeth Wehrle; Vijay Modur; John M Goldman; Jerald P Radich Journal: Blood Date: 2010-08-02 Impact factor: 22.113
Authors: B Hanfstein; M C Müller; R Hehlmann; P Erben; M Lauseker; A Fabarius; S Schnittger; C Haferlach; G Göhring; U Proetel; H-J Kolb; S W Krause; W-K Hofmann; J Schubert; H Einsele; J Dengler; M Hänel; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; S Branford; T P Hughes; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; S Saußele; A Hochhaus Journal: Leukemia Date: 2012-03-26 Impact factor: 11.528
Authors: Rüdiger Hehlmann; Michael Lauseker; Susanne Jung-Munkwitz; Armin Leitner; Martin C Müller; Nadine Pletsch; Ulrike Proetel; Claudia Haferlach; Brigitte Schlegelberger; Leopold Balleisen; Mathias Hänel; Markus Pfirrmann; Stefan W Krause; Christoph Nerl; Hans Pralle; Alois Gratwohl; Dieter K Hossfeld; Joerg Hasford; Andreas Hochhaus; Susanne Saussele Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: A Hochhaus; A Reiter; S Saussele; A Reichert; M Emig; J Kaeda; B Schultheis; U Berger; P C Shepherd; N C Allan; R Hehlmann; J M Goldman; N C Cross Journal: Blood Date: 2000-01-01 Impact factor: 22.113
Authors: Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann Journal: Blood Date: 2013-06-26 Impact factor: 22.113
Authors: L Kalmanti; S Saussele; M Lauseker; M C Müller; C T Dietz; L Heinrich; B Hanfstein; U Proetel; A Fabarius; S W Krause; S Rinaldetti; J Dengler; C Falge; E Oppliger-Leibundgut; A Burchert; A Neubauer; L Kanz; F Stegelmann; M Pfreundschuh; K Spiekermann; C Scheid; M Pfirrmann; A Hochhaus; J Hasford; R Hehlmann Journal: Leukemia Date: 2015-02-13 Impact factor: 11.528
Authors: Susanne Saussele; Rüdiger Hehlmann; Alice Fabarius; Sabine Jeromin; Ulrike Proetel; Sebastien Rinaldetti; Katharina Kohlbrenner; Hermann Einsele; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Elisabeth Oppliger Leibundgut; Dominik Heim; Stefan W Krause; Wolf-Karsten Hofmann; Joerg Hasford; Markus Pfirrmann; Martin C Müller; Andreas Hochhaus; Michael Lauseker Journal: Leukemia Date: 2018-02-26 Impact factor: 11.528
Authors: R Hehlmann; M Lauseker; S Saußele; M Pfirrmann; S Krause; H J Kolb; A Neubauer; D K Hossfeld; C Nerl; A Gratwohl; G M Baerlocher; D Heim; T H Brümmendorf; A Fabarius; C Haferlach; B Schlegelberger; M C Müller; S Jeromin; U Proetel; K Kohlbrenner; A Voskanyan; S Rinaldetti; W Seifarth; B Spieß; L Balleisen; M C Goebeler; M Hänel; A Ho; J Dengler; C Falge; L Kanz; S Kremers; A Burchert; M Kneba; F Stegelmann; C A Köhne; H W Lindemann; C F Waller; M Pfreundschuh; K Spiekermann; W E Berdel; L Müller; M Edinger; J Mayer; D W Beelen; M Bentz; H Link; B Hertenstein; R Fuchs; M Wernli; F Schlegel; R Schlag; M de Wit; L Trümper; H Hebart; M Hahn; J Thomalla; C Scheid; P Schafhausen; W Verbeek; M J Eckart; W Gassmann; A Pezzutto; M Schenk; P Brossart; T Geer; S Bildat; E Schäfer; A Hochhaus; J Hasford Journal: Leukemia Date: 2017-08-14 Impact factor: 11.528
Authors: A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann Journal: Leukemia Date: 2020-03-03 Impact factor: 11.528